Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.23). On average, analysts expect Barinthus Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Barinthus Biotherapeutics Price Performance
BRNS traded down $0.11 during trading on Friday, reaching $1.34. 25,082 shares of the stock traded hands, compared to its average volume of 3,845,176. The stock has a market cap of $54.06 million, a price-to-earnings ratio of -0.77 and a beta of -0.73. Barinthus Biotherapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.92. The stock's 50-day simple moving average is $1.17 and its two-hundred day simple moving average is $1.01.
About Barinthus Biotherapeutics
(
Get Free Report)
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Further Reading
Before you consider Barinthus Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Barinthus Biotherapeutics wasn't on the list.
While Barinthus Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access